Technetium Containing (at. No. 43; Tc) Patents (Class 534/14)
  • Publication number: 20120208988
    Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
    Type: Application
    Filed: November 11, 2011
    Publication date: August 16, 2012
    Applicant: MOLECULAR INSIGHTS PHARMACEUTICALS, INC.
    Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
  • Patent number: 8232360
    Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: July 31, 2012
    Assignee: Research Foundation of State University of N.Y.
    Inventors: Nicole S. Sampson, Kathlyn A. Parker
  • Patent number: 8211402
    Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: July 3, 2012
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
  • Patent number: 8211401
    Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: July 3, 2012
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
  • Publication number: 20120142641
    Abstract: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.
    Type: Application
    Filed: June 7, 2010
    Publication date: June 7, 2012
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Subramanian Venkatraman, Say Chye Joachim Loo
  • Publication number: 20120128583
    Abstract: The present invention relates to DTPA derivatives capable of forming complexes by combining with metals and the like, metal complexes formed by combining with the DTPA derivatives, MR and CT contrast agents including gold (Au) nano-particles of which surfaces are coated with the metal complexes, and a method for manufacturing the same. The MR and CT contrast agents according to the present invention have a high magnetic relaxation rate, thereby providing an excellent contrast enforcement effect and a long image acquisition time. Furthermore, the MR and CT contrast agents are not toxic to the human body, and are image contrast agents of dual molecules capable of being applied to both MR and CT.
    Type: Application
    Filed: December 13, 2009
    Publication date: May 24, 2012
    Applicant: Kyungpook National University Industry Academic Cooperation Foundation
    Inventors: Tae Jung Kim, Yong Min Jang, Ji Ae Park
  • Publication number: 20120093725
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: April 10, 2009
    Publication date: April 19, 2012
    Applicant: Inserm (Institut National de la Sante et de la Recherche Medicale
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Publication number: 20120077967
    Abstract: Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the use of 99mTc radiopharmaceuticals of the invention for SPECT imaging.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 29, 2012
    Applicant: GE HEALTHCARE LIMITED
    Inventor: RAJIV BHALLA
  • Patent number: 8119103
    Abstract: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to the linker.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: February 21, 2012
    Assignee: Mallinckrodt LLC
    Inventor: Dennis A. Moore
  • Publication number: 20110300072
    Abstract: Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO2 and SO3, preferably from N, S and SO3 and most preferably from N and SO3; n may be 0 or 1, R1 is a group selected from formula (II) and formula (III) and R2 is a group selected from H and formula (IV) since the aforesaid serves for the production of a formulation used as a specific marker in the case of neurodegenerative diseases and tau pathologies.
    Type: Application
    Filed: July 22, 2009
    Publication date: December 8, 2011
    Applicant: SERVICIOS CIENTIFICOS NEUROINNOVATION LTDA.
    Inventors: Ricardo Maccioni Baraona, Leonel Rojo, Rodrigo Kuljis Azocar
  • Patent number: 8048405
    Abstract: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4?/or ReO4?, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4?/or ReO4? avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 1, 2011
    Assignee: Atomic Energy Council-Institute of Nuclear Energy Research
    Inventors: Tsai-Yueh Luo, I-Chung Tang, Show-Wen Liu, Yu-Lung Wu, Cheng-Hsien Lin, Cheng-Fang Hsu, Kwei-Luen Hsu, Chang-Mau Sheng, Ching-Jun Liou, Te-Sheng Liang
  • Publication number: 20110262347
    Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 27, 2011
    Inventors: Erkki Ruoslahti, Lilach Agemy, Dinorah Friedmann-Morviniski, Venkata Ramana Kotamraju, Kazuki Sugahara, Inder Verma
  • Publication number: 20110251363
    Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.
    Type: Application
    Filed: July 17, 2007
    Publication date: October 13, 2011
    Inventors: Nicole S. Sampson, Kathlyn A. Parker
  • Publication number: 20110236312
    Abstract: The invention provides compounds that comprise a 4?-thio nucleoside that is a derivative of 4?-thiothymidine or 4?-thio-2?-deoxyuridine comprising a positron or single photon emitting radioisotope or corresponding non-radioactive isotope attached via a triazole link to the N-3 position. Methods for preparing such compounds and uses of the compounds in medicine are also provided.
    Type: Application
    Filed: August 28, 2009
    Publication date: September 29, 2011
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Eric Ofori Aboagye, Graham Smith
  • Publication number: 20110236308
    Abstract: The present invention relates generally to chelation compounds, radionuclide metal chelate compounds, i.e., complexes, and radiolabeled targeting moieties, i.e., conjugates, formed therefrom, and methods of using these compounds, complexes and conjugates for diagnostic and therapeutic purposes. This invention is more particularly related to aryl bidentate isonitrile metal complexes generated by a chemical interaction of a metal salt oxide or weak complex of the metal with aryl isonitrile bidentate ligands.
    Type: Application
    Filed: April 17, 2007
    Publication date: September 29, 2011
    Applicant: The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman, Bhaskar C. Das
  • Publication number: 20110229410
    Abstract: One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
    Type: Application
    Filed: January 20, 2011
    Publication date: September 22, 2011
    Inventors: John W. Babich, Kevin P. Maresca
  • Patent number: 8022211
    Abstract: Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the us of 99mTc radiopharmaceuticals of the invention for SPECT imaging.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: September 20, 2011
    Assignee: GE Healthcare Limited
    Inventor: Rajiv Bhalla
  • Publication number: 20110206604
    Abstract: A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 25, 2011
    Inventor: Jianping Ruan
  • Publication number: 20110168984
    Abstract: Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.
    Type: Application
    Filed: August 25, 2010
    Publication date: July 14, 2011
    Applicants: The Regents of the University of Michigan, The University of Southern California
    Inventors: Stephen R. Forrest, Jeramy D. Zimmerman, Mark E. Thompson, Viacheslav Diev, Kenneth Hanson
  • Publication number: 20110160579
    Abstract: A device for the investigation of an object uses a microwave transmitter, a microwave receiver, a control device and a contrast medium. The microwave transmitter and the microwave receiver are controlled by the control device. In one embodiment, the following steps maybe implemented: introduction of the contrast medium into the object under investigation; transmission of a microwave signal into the object under investigation by the microwave transmitter; scattering of the microwave signal by the object under investigation and by the contrast medium; and/or reception of the scattered microwave signal by the microwave receiver.
    Type: Application
    Filed: June 2, 2009
    Publication date: June 30, 2011
    Applicant: ROHDE & SCHWARZ GMBH & CO. KG
    Inventors: Martin Leibfritz, Gerd Hechtfischer, René Krupka, Jan Prochnow
  • Publication number: 20110158907
    Abstract: This invention relates to a method of imaging amyloid deposits and to diphenyl-heteroaryl compounds, and methods of making radiolabeled diphenyl-heteroaryl compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
    Type: Application
    Filed: April 18, 2008
    Publication date: June 30, 2011
    Applicant: The Trustees of the Univeristy of Pennsylvania
    Inventors: Hank F. Kung, Mei-Ping Kung, Wenchao Qu
  • Publication number: 20110144483
    Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).
    Type: Application
    Filed: November 15, 2010
    Publication date: June 16, 2011
    Inventor: Mark M. GOODMAN
  • Publication number: 20110097265
    Abstract: A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.
    Type: Application
    Filed: May 13, 2010
    Publication date: April 28, 2011
    Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
    Inventors: Mei-Hui Wang, Wuu-Jyh Lin, Chuan-Yi Chien, Hung-Man Yu, Reiko Takasaka Lee, Yuan-Chuan Lee
  • Patent number: 7922998
    Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: April 12, 2011
    Assignee: Bracco Imaging S.p.A.
    Inventors: Enrico Cappelletti, Luciano Lattuada, Karen E. Linder, Edmund Marinelli, Palaniappa Nanjappan, Natarajan Raju, Kondareddiar Ramalingam, Rolf E. Swenson, Michael Tweedle
  • Publication number: 20110065904
    Abstract: H3LMN series compounds used as radioactive agents for treatment of liver cancer and a manufacturing method thereof are revealed. 2-thioethylamine hydrochloride is reacted with triphenylmethanol for protection of thiol to obtain 2-[(triphenylmethyl)thio]ethylamine. Then obtain N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide by a transamidation reaction between 2-[(triphenylmethyl)thio]ethylamine and chloroactyl chloride. Next produce a amine-amide-thiol ligand-N-[2-((triphenylmethyl)thio)ethyl][2-((triphenylmethyl)thio)ethylamino]acetamide by a substitution reaction of N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide and 2-[(triphenylmethyl)thio]ethylamine. After respective reaction with 1-bromotetradecane, 1-bromohexadecane and ethyl 16-bromohexadecanoate, H3LMN series compounds are obtained. These amine-amide-dithiols quadridentate ligands can react with MO3+ (M=Tc or Re) to produce electrically neutral complexes.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 17, 2011
    Inventors: Show-Wen Liu, Cheng-Hsien Lin, Tsyh-Lang Lin, Cheng-Fang Hsu
  • Publication number: 20110065680
    Abstract: A method for synthesizing a complex having the formula: [L3MO3]? wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from ?2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or b) reaction of pertechnetate or perrhenate with a Lewis acid and L3, wherein the synthesis (a) or (b) is carried out in an aqueous medium.
    Type: Application
    Filed: March 10, 2009
    Publication date: March 17, 2011
    Inventors: Roger Alberto, Henrik Braband
  • Publication number: 20110064657
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Application
    Filed: June 26, 2008
    Publication date: March 17, 2011
    Applicant: The Johns Hopkins University
    Inventors: Martin Gilbert Pomper, Ray Sangeeta, Ronnie C. Mease, Catherine Foss
  • Patent number: 7893223
    Abstract: Compounds of general formula (I): with substituents as defined herein and their chelates with bi-trivalent ions of the metal elements of atomic numbers 20 to 31, 39, 42, 43, 44, 49, and 57 to 83, and radioisotopes chosen among 203Pb, 67Ga, 68Ga, 72As, 111In, 113In, 90Y, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, 111Ag, 199Au, 161Tb, 51Cr, 167Tm, 141Ce, 168Yb, 88Y, 165Dy, 166Dy, 97Ru, 103Ru, 186Re, 99mTc, 211Bi, 213Bi, 214Bi, 105Rh, 109Pd, 177mSn, 177Sn and 199Au, as well as the salts thereof with physiologically compatible bases or acids.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: February 22, 2011
    Assignee: Bracco Imaging S.p.A.
    Inventors: Giovanni Battista Giovenzana, Giovanni Palmisano, Massimo Sisti, Camilla Cavallotti, Silvio Aime, Luisella Calabi, Rolf Swenson, Ramalingam Kondareddiar, Luciano Lattuada, Pierfrancesco Morosini
  • Publication number: 20100254906
    Abstract: New pharmaceutical compositions based on grafted polysaccharides and methods of preparing such compositions are provided. Methods of using the compositions in medical imaging—for example in scintigraphy and in internal radiotherapy—are also provided.
    Type: Application
    Filed: July 25, 2008
    Publication date: October 7, 2010
    Applicant: LABORATOIRES CYCLOPHARMA
    Inventors: Benoît Denizot, Franck Lacoeuille, Jean Jacques Le Jeune, François Hindre
  • Patent number: 7803351
    Abstract: Novel blood-brain barrier permeant amyloid-targeting peptides and peptide conjugates are described. The peptide conjugates include a radioisotope or other label in a stable complex that translocates across brain capillary endothelial cell monolayers. The labeled peptide conjugate binds to amyloid plaques (A?) associated with Alzheimer's disease, and is useful for the targeted delivery of therapeutic and diagnostic molecules into the brain.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: September 28, 2010
    Assignee: Washington University
    Inventors: Vijay Sharma, David Piwnica-Worms
  • Publication number: 20100228012
    Abstract: The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.
    Type: Application
    Filed: June 4, 2009
    Publication date: September 9, 2010
    Inventor: John W. BABICH
  • Publication number: 20100221181
    Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.
    Type: Application
    Filed: September 23, 2008
    Publication date: September 2, 2010
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventor: Frank Olaf Thiele
  • Patent number: 7785566
    Abstract: The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: August 31, 2010
    Assignee: GE Healthcare, Inc.
    Inventors: Alan Cuthbertson, Bard Indrevoll, Morten Eriksen
  • Publication number: 20100202965
    Abstract: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N?,N?,N??-tetraacetic acid) complex of Formula I, or a radioisotope derivative of Formula I.
    Type: Application
    Filed: February 12, 2009
    Publication date: August 12, 2010
    Applicant: General Electric Company
    Inventors: Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Kenneth Michael Fish, Nicole Evelyn Barnhardt, John V. Frangioni, Carrie S. Vooght
  • Patent number: 7767796
    Abstract: The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalized at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimize lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: August 3, 2010
    Assignee: GE Healthcare Limited
    Inventors: Anthony Eamonn Storey, Harry John Wadsworth, Nigel Anthony Powell, Philip Duncanson
  • Publication number: 20100183509
    Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.
    Type: Application
    Filed: December 4, 2009
    Publication date: July 22, 2010
    Inventors: John W. BABICH, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
  • Publication number: 20100178246
    Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.
    Type: Application
    Filed: December 4, 2009
    Publication date: July 15, 2010
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
  • Publication number: 20100178247
    Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.
    Type: Application
    Filed: December 4, 2009
    Publication date: July 15, 2010
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
  • Patent number: 7744853
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: June 29, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • Publication number: 20100160615
    Abstract: A bisphosphonoaminc compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.
    Type: Application
    Filed: January 20, 2006
    Publication date: June 24, 2010
    Applicant: NIHON MED-PHYSICS CO., LTD.
    Inventors: Francesco Tisato, Fiorenzo Refosco, Cristina Bolzati, Stefania Agostini, Marina Porchia, Mario Cavazza-Ceccato, Shinji Tokunaga
  • Publication number: 20100143249
    Abstract: The present invention is directed towards novel folate-conjugates of formula I wherein F is a folate or derivative thereof, Z1, Z2, Z3 are independently of each other C or N, S1 to S4 are independently of each other a single bond or a spacer, Ra, Ra?, and Rb are donor groups and/or another group F, Rc is optionally another group F and n is 1 or 2. The invention further contemplates the corresponding metal-chelate complexes as well as pharmaceutical compositions thereof, and their uses in diagnostic imaging and radiotherapy.
    Type: Application
    Filed: April 11, 2008
    Publication date: June 10, 2010
    Applicant: MERCK EPROVA AG
    Inventors: Rudolf Moser, Roger Schibli, Cristina Magdalena Muller, Viola Groehn, Urs Michel, Christoph Sparr, Thomas Leighton Mindt
  • Patent number: 7731936
    Abstract: Provided are radiolytically and metabolically stable metal complexes based on tetrathiol ligands useful for nuclear medical diagnostics and in endoradionuclide therapy. Methods for their preparation are also provided. The complexes can have a central ligand, Y, that can be 99mTcO, 186ReO, 188ReO, 99mTcN, 186ReN or 188ReN.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: June 8, 2010
    Assignee: Forschungszentrum Rossendorf E,V
    Inventors: Tobias Heinrich, Bernd Johannsen, Hans-Juergen Pietzsch, Sepp Seifert, Hartmut Spies
  • Patent number: 7718160
    Abstract: The invention, in one aspect, relates to radiolabeled compounds. The invention also relates to radiolabeled liposomes and methods of making and using thereof. The invention also relates to kits for preparing radiolabeled liposomes.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: May 18, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Ande Bao, William T. Phillips, Beth Goins
  • Publication number: 20100104512
    Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m—X1p1X2p2X3p3X4p4]z? z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.
    Type: Application
    Filed: October 9, 2007
    Publication date: April 29, 2010
    Applicant: Centre National De La Recherche Scientifique
    Inventors: Delphine Felder-Flesch, Jerome Steibel, Annabelle Bertin
  • Publication number: 20100074842
    Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.
    Type: Application
    Filed: November 23, 2007
    Publication date: March 25, 2010
    Inventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
  • Publication number: 20100074843
    Abstract: The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
    Type: Application
    Filed: April 30, 2009
    Publication date: March 25, 2010
    Applicant: Siemens Medical Solutions USA, Inc.
    Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Umesh B. Gangadharmath, Gang Chen, Vani P. Mocharla, Dhanalakshmi Kasi, Peter J.H. Scott, Qianwa Liang
  • Patent number: 7674886
    Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: March 9, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventor: Sudhakar Kasina
  • Publication number: 20100055035
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Application
    Filed: September 21, 2009
    Publication date: March 4, 2010
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
  • Publication number: 20100040542
    Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.
    Type: Application
    Filed: October 1, 2009
    Publication date: February 18, 2010
    Applicant: GE HEALTHCARE LIMITED
    Inventors: COLIN MILL ARCHER, HARRY JOHN WADSWORTH, TORGRIM ENGELL
  • Patent number: RE43274
    Abstract: Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using photodynamic methods. In particular, photosensitizer compounds that collect in hyperproliferative tissue are provided. In another embodiment, compounds that absorb light at a wavelength of from about 700 to about 850 nm are provided. In a further embodiment, compounds that are detectable by magnetic resonance imaging are provided.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: March 27, 2012
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, William R. Potter, Thomas J. Dougherty